Anna B. Birg

Anna B. Birg

Auto-generated profile, based on publicly available information

Anna B. Birg

Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Patient-Oriented Medicine and Pharmacy
Verified
Journal Article
Open access
PDF file
IPI. E. Pleshchev
I. E. Pleshchev
VNVladimir Nikolenko
Vladimir Nikolenko
EAE. E. Achkasov
E. E. Achkasov
ASA. N. Shkrebko
A. N. Shkrebko
TPT. N. Pleshchevа
T. N. Pleshchevа
ЧСЧ. Синьлян
Ч. Синьлян
The aim of the current descriptive review was to identify the role of nutrition in the prevention and treatment of sarcopenia in the elderly. Most of the publications included in this review show that protein and vitamin D intake, as well as a healthy and balanced diet, plays an important protective role against the development of sarcopenia. However, current scientific evidence is insufficient to draw sound conclusions. Although the role of nutrition in sarcopenia has been assessed in scientific publications over the past decade, most of the studies conducted are highly heterogeneous and had small sample sizes. Larger meta-analyses and randomized trials with strict inclusion criteria must better describe the role of nutrition in the development and treatment of sarcopenia. In conclusion, general recommendations on nutrition are given. A literature search was conducted in three electronic databases PubMed, Cochrane Library, Scopus, for the period from 2012 to December 1, 2022. Secondary sources included articles cited in articles extracted from the above sources. Inclusion criteria were crossover or cohort studies involving individuals ≥60 years of age. There were no restrictions on the language bias of the publication. Search strategy: key words used to describe the condition of the participants were: «old age», «infirmity», and «sarcopenia».

3 December 2025 in Russian Journal of Cardiology and Cardiovascular Surgery
Verified
Journal Article
Closed access
SSS.A. Shidlovskaya
S.A. Shidlovskaya
DMDenis MD
Denis MD
MSM.V. Serova
M.V. Serova
YSYu.S. Sazonova
Yu.S. Sazonova
PKPhilipp Kopylov
Philipp Kopylov
ABA.B. Birg
A.B. Birg
Objective. To analyze the incidence of hemorrhagic (HC) and thromboembolic complications (TC) in patients with atrial fibrillation undergoing pulmonary vein isolation or catheter ablation of cavotricuspid isthmus depending on perioperative anticoagulation. Material and methods. This is a prospective study of patients undergoing catheter ablation. The first group included patients in 2016—2018 who underwent perioperative interruption of anticoagulation with injection of low molecular weight heparins. The second group included patients in 2021—2022 who underwent surgical treatment under regular intake of anticoagulant. The incidence of intraoperative and delayed TC and HC was analyzed. We compared effectiveness and safety of various perioperative anticoagulation regimens and assessed significance of various factors of complications. Primary endpoint was major HC and any arterial thromboembolic event, secondary endpoint — minor HC. Results. The first group included 78 patients (12 (15.4%) patients received warfarin, 66 (74.6%) ones received direct oral anticoagulants (DOACs)). The second group included 92 patients (1 (1.1%) received warfarin, 91 (98.9%) received DOACs). Patients in the first group were significantly more likely to achieve primary (p=0.0456) and secondary (p=0.0256) endpoints. No factors influencing the incidence of major HC were identified. Intraoperative electrical cardioversion significantly affected the incidence of minor HC (p=0.007), patient age (p=0.018) and anticoagulation with warfarin upon admission (p=0.040) — the incidence of TC. Conclusion. Minimally interrupted administration of anticoagulants significantly reduces the number of TC and HC.

25 June 2026 in The Clinician
Verified
Journal Article
Closed access
PDF file
SIShevket Girey Ibraimov
Shevket Girey Ibraimov
ИИИбраимов Ш. Г. И.
Ибраимов Ш. Г. И.
DSD. R. Stepanov
D. R. Stepanov
СРСтепанов Д. Р.
Степанов Д. Р.
EBE. D. Bichugova
E. D. Bichugova
АААндреев Д. А.
Андреев Д. А.
Aim. To evaluate clinical, demographic, laboratory and instrumental characteristics, treatment, and outcomes of patients with acute decompensated heart failure depending on left ventricular ejection fraction. Material and methods. A consecutive retrospective study was conducted including patients aged 18 years hospitalized with acute decompensated heart failure to a multidisciplinary hospital between December 1, 2019 and December 1, 2021. All patients were divided into 3 groups according to left ventricular ejection fraction, followed by an analysis of patient characteristics. Results. A total of 486 patients were included (55 % men); mean age was 72 ± 12 years. The number of patients with heart failure with reduced ejection fraction was 235 (48 %), with mildly reduced ejection fraction – 117 (24 %), and with preserved ejection fraction – 134 (28 %). More than 60 % of patients required admission to the intensive care unit. The groups differed in sex, age, presence of coronary artery disease, postinfarction cardiosclerosis, history of myocardial revascularization, presence of infection at admission, as well as in physical examination findings, laboratory and instrumental parameters; however, no differences in mortality were observed between the groups (p 0.05). Conclusion. Despite the fact that patients with heart failure with reduced ejection fraction had more severe condition at admission per clinical, laboratory, and instrumental parameters, more often had a history of coronary artery disease, postinfarction cardiosclerosis, and myocardial revascularization, more frequently required inotropic / vasopressor support, and had longer hospital stays, mortality rates were comparable between the groups.

23 April 2026 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DSDmitri Shchekochikhin
Dmitri Shchekochikhin
ABAnna B. Birg
Anna B. Birg
TETamerlan Erdniev
Tamerlan Erdniev
ANAnna A. Nartova
Anna A. Nartova
Andrey N. RozhkovAndrey N. Rozhkov
Andrey N. Rozhkov
КЮКопылов Филипп Юрьевич
Копылов Филипп Юрьевич
Background: Risk stratification for adverse cardiovascular outcomes is a key challenge in clinical cardiology. In addition to traditional risk scores, various other markers, including circulating microRNAs, have been actively investigated in recent years as a potential tool for personalized prognosis. Aim: To assess the prognostic value of baseline microRNA levels in patients with asymptomatic coronary atherosclerosis detected by multislice computed tomography (MSCT) during long-term follow-up. Methods: The retrospective analysis included data from 30 patients with asymptomatic coronary atherosclerosis confirmed by MSCT. At baseline, plasma levels of 15 circulating microRNAs were measured in all patients using NucleoSpin miRNA Plasma kits (MACHEREY-NAGEL, Germany): miR-195p, miR-126-3p, miR-205-5p, miR-126-5p, miR-21-5p, miR-143-3p, miR-223-3p, miR-145-5p, miR-29b-3p, miR-146a-5p, miR-92a-3p, miR-150-5p, miR-23a-3p, miR-181b-5p, miR-451a. Information on clinical outcomes within 5 years after enrollment was obtained from the Unified State Health Information System (USHIS, Russia). Endpoints were acute myocardial infarction (AMI), stroke, all-cause mortality, and a composite endpoint (AMI / stroke / mortality). Results: Among the 30 patients with asymptomatic atherosclerosis on MSCT (mean age 70 ± 9.8 years, 11 men), adverse outcomes were recorded in 7 patients during the 5-year follow-up, while 23 patients remained event-free. In univariate Cox analysis, only two microRNAs showed a statistically significant association with the outcome (AMI, stroke, and all-cause mortality): for miR-143-3p, the hazard ratio (HR) was 0.724 (95% confidence interval [CI] 0.539–0.972; p = 0.032); for miR-451a, HR was 27.872 (95% CI 1.125–690.637; p = 0.042). ROC analysis revealed borderline significance in predicting adverse events for miR-143-3p (sensitivity 71.4%, specificity 73.9%; p = 0.059) and for miR-451a (sensitivity 71.4%, specificity 87.0%; p = 0.066). In multivariable Cox regression adjusted for the Framingham risk score, a higher miR-143-3p level was independently associated with a reduced risk of all-cause death (HR 0.71; 95% CI 0.52–0.96). After adjustment for the Multi-Ethnic Study of Atherosclerosis (MESA) risk score, the high-risk category of miR-143-3p was associated with an increased risk of reaching the composite endpoint (HR 607.997; 95% CI 4.606–8024.582). Conclusion: Among the 15 microRNAs studied, miR-143-3p and miR-451a demonstrated an association with the development of adverse outcomes in patients with asymptomatic coronary atherosclerosis. These findings point to the potential prognostic value of these microRNAs, but require confirmation in studies with larger patient samples.